HC Stocks in the Rumor- Boston Scientific Corporation (BSX), Johnson & Johnson (JNJ)
Shares of Boston Scientific Corporation (NYSE:BSX) ended Thursday session in red amid volatile trading. The shares closed down -0.03 points or -0.13% at $23.15 with 10.03 million shares getting traded. Post opening the session at $23.05, the shares hit an intraday low of $22.88 and an intraday high of $23.25 and the price vacillated in this range throughout the day. The company has a market cap of $31.53 billion and the numbers of outstanding shares have been calculated to be 1.36 billion shares.
Boston Scientific Corporation (BSX) develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems.
Shares of Johnson & Johnson (NYSE:JNJ) ended Thursday session in green amid volatile trading. The shares closed up +0.29 points or 0.25% at $118.26 with 7.39 million shares getting traded. Post opening the session at $117.54, the shares hit an intraday low of $117.28 and an intraday high of $119.20 and the price vacillated in this range throughout the day. The company has a market cap of $324.45 billion and the numbers of outstanding shares have been calculated to be 2.74 billion shares.
Johnson & Johnson (JNJ) announced a new five-year commitment to help advance the United Nations Sustainable Development Goals to help improve the health and well-being of men, women and children around the world. Johnson & Johnson is dedicating its expertise and innovations to ignite global partnerships and catalyze efforts through a variety of new implementation plans, targets and metrics. The announcement comes along with an expanded commitment by Johnson & Johnson to further strengthen the resilience of refugee and displaced children and their families in Syria and its neighboring countries where the need is greatest.
“Johnson & Johnson is committed to creating greater access to quality health care across the globe,” said Johnson & Johnson Chairman and CEO Alex Gorsky. “Beyond developing medicines, equipment and vaccines, we’re in communities helping expectant mothers take better care of themselves and their babies during pregnancy. We’re training nurses and doctors to identify and treat diseases, and also funding medical research. We’re proud to take a leading role with the world community in this effort, which will go a long way toward creating a healthier society.”